PHGE
BiomX Inc.
$0.63
+1.28%
2026-05-08
About BiomX Inc.
BiomX Inc., a clinical-stage biopharmaceutical company, develops phage-based therapies using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company's phage-based therapies include fixed cocktail therapy, which involves developing a single product containing a fixed number of selected phages to cover a range of bacterial strains; and personalized therapy, which involves developing a large library of phages from which single optimal phages are personally matched to treat specific patients. It develops BX011, a fixed multi-phage cocktail, which is in Phase 2a trial for the treatment of diabetic foot infections; and BX211, a phage therapy, which is in Phase 2 trial for the treatment of diabetic foot osteomyelitis. BiomX Inc. was founded in 2015 and is based in Dover, Delaware.
Key Fundamentals
Forward P/E
-0.05
EPS (TTM)
$-37.05
ROE
-316.9%
Profit Margin
0.0%
Beta
1.03
Market Cap
$5.4M
Avg Volume (10D)
589K
Recent Breakout Signals
No recent breakout signals detected for PHGE.
Recent Price Range (60 Days)
60D High
$8.10
60D Low
$0.59
Avg Volume
202K
Latest Close
$0.63
Get breakout alerts for PHGE
Sign up for Breakout Scanner to receive daily notifications when PHGE triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
BiomX Inc. (PHGE) is listed on the New York Stock Exchange (NYSE). Breakout Scanner monitors PHGE daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. PHGE operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.